Mr. Jared Bearss

Speech title: Early Clinical Evaluation of HT-6184 a Potent, Selective, Orally Bioavailable, Allosteric Inhibitor of Nek7/NLRP3
Affiliation: Chief Operating Officer, Halia Therapeutics, USA
Biography: Jared Bearss co-founded Halia Therapeutics in 2017. His prior industry experience includes co-founding Wasatch Scientific and managing the genomic biology department and projects for Code Nutrition. Jared also has experience working in the academic field of life sciences and was Sr. Research Analyst, and Lab Manager at the Huntsman Cancer Institute.
Jared’s experience in both industry and academic sectors of the life sciences field provided him with many areas of expertise including genomics, cell biology, cell culture, western blotting, and molecular biology. His scientific background and entrepreneurial spirit got him interested in scaling pharmaceutical startups and managing technical and organizational aspects of company development.
Jared has a Bachelor of Science in neuropsychology/neurophysiology from Utah Valley University and is an MBA Business Executive from the David Eccles School of Business at the University of Utah.

We are thrilled to announce that Mr. Jared Bearss will present at the 13th Emirates Pathology, Digital Pathology & Cancer Conference, which is CME/CPD recognized, from December 15-17, 2023, in Holiday Inn Dubai, Al Barsha, UAE & Virtual. WhatsApp us at
In-person Register link here:
Register virtually link here:

#Cancer #Education #Digitalpathology #EPUCG #biochemistry #usmlestep #medstudent #laboratory #medschool #pathologist #medicalschool #radiology #biology #microscope #Breastpathology

Unified Citation Journals is a platform for the latest discoveries in Technology, Science, engineering, medicine, medical clinical, and advancing discoveries and health. We at Unified Citation Journals ensure the advancement of healthcare and improve performance for the benefit of humanity.
Visit here:

Speaker Details